JPMorgan lowered the firm’s price target on Viking Therapeutics (VKTX) to $75 from $80 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Navigates Regulatory Risks Amid U.S. Policy Shifts
- Viking Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges
- Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley
- Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking Therapeutics
- Viking Therapeutics offered ‘transformative’ Q3 update, says Cantor Fitzgerald